Lan, Taijin
Arastu, Sara
Lam, Jarrick
Kim, Hyungsin
Wang, Wenping
Wang, Samuel http://orcid.org/0000-0001-7089-4597
Bhatt, Vrushank
Lopes, Eduardo Cararo http://orcid.org/0000-0002-5316-5146
Hu, Zhixian
Sun, Michael
Luo, Xuefei
Ghergurovich, Jonathan M. http://orcid.org/0000-0002-6565-2275
Su, Xiaoyang http://orcid.org/0000-0001-8081-1396
Rabinowitz, Joshua D. http://orcid.org/0000-0002-1247-4727
White, Eileen http://orcid.org/0000-0003-2961-3065
Guo, Jessie Yanxiang http://orcid.org/0000-0001-9212-7954
Article History
Received: 4 October 2023
Accepted: 28 June 2024
First Online: 12 July 2024
Competing interests
: E.W. is a stockholder in a founder of Vescor Therapeutics. J.D.R. is an advisor and stockholder in Colorado Research Partners, L.E.A.F. Pharmaceuticals, Bantam Pharmaceuticals, Rafael Pharmaceuticals; a paid consultant of Third Rock Ventures; a founder, director and stockholder of Farber Partners, Serien Therapeutics and Sofro Pharmaceuticals; a founder and stockholder in Empress Therapeutics; and a director of the Princeton University–PKU Shenzhen collaboration. The Rabinowitz lab at Princeton University and the Princeton University-PKU Shenzhen collaboration have discovered and generated intellectual property regarding G6PD inhibitors. Other authors have no conflict of interest to declare.